http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103570705-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e2b7361978d9ff4829de745aac79548
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-06
filingDate 2012-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6001a5f2cdba9d3e840a161f1c5257d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6347a5044cb480c4ecd27e0721fb65d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f130db1fb4511b112c4f6cba390b8314
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aebaf0f2820c229e3960feab38d15bd3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3812d2d58c3783a9920481ef43813ce0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02eddfc190d4c5f17c7f6a675432f7a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2cc3f7bbb052ef00a3f10a950d173f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e164cd03e5228eb4d5dcea4150b9a1f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29bb34df9fe2a2747ed61eccc39c37ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ecd8efe9207d60b24cbac7bffa8e7381
publicationDate 2014-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-103570705-A
titleOfInvention Substituted N-((1',3'-heterazol-4'-yl)-methyl)-4-benzoylhexahydropyridine compounds and uses thereof
abstract The present invention relates to substituted N-((1',3'-heterazol-4'-yl)-methyl)-4-benzoyl hexahydropyridine compounds represented by general formula I, and the present invention also relates to the The preparation method of the above-mentioned compound and its use in the preparation of anti-tuberculosis drugs. The compound of the present invention is not only effective against tuberculosis sensitive strains, but also effective against drug-resistant strains that are resistant to isoniazid and rifampicin and other traditional first-line anti-tuberculosis drugs, and is a new type of anti-tuberculosis compound with great application prospects .
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114516858-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110105347-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110105347-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023140709-A1
priorityDate 2012-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101939317-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011251182-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0241053-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004033427-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009023707-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426023574
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID408181285
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4220841
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID43558772

Total number of triples: 35.